Aprea Therapeutics, Inc. Financials
Financial Health Signals
Aprea Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Aprea Therapeutics, Inc. generates $1.05 in operating cash flow (-$13.6M OCF vs -$13.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Aprea Therapeutics, Inc. (APRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aprea Therapeutics, Inc.'s EBITDA was -$14.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.5% from the prior year.
Aprea Therapeutics, Inc. generated -$13.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 10.6% from the prior year.
Aprea Therapeutics, Inc. reported -$13.0M in net income in fiscal year 2024. This represents an increase of 9.3% from the prior year.
Aprea Therapeutics, Inc. earned $-2.45 per diluted share (EPS) in fiscal year 2024. This represents an increase of 38.0% from the prior year.
Aprea Therapeutics, Inc. held $22.8M in cash against $0 in long-term debt as of fiscal year 2024.
Aprea Therapeutics, Inc. had 5M shares outstanding in fiscal year 2024. This represents an increase of 46.7% from the prior year.
Aprea Therapeutics, Inc. invested $9.4M in research and development in fiscal year 2024. This represents an increase of 22.8% from the prior year.
Aprea Therapeutics, Inc. invested $15K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 83.4% from the prior year.
APRE Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.6M-42.4% | $2.8M | N/A | $2.1M | N/A | $1.1M | N/A | $6.0M |
| SG&A Expenses | $1.5M-7.8% | $1.6M | N/A | $1.7M | N/A | $3.1M | N/A | $3.4M |
| Operating Income | -$3.1M+23.9% | -$4.1M | N/A | -$3.5M | N/A | -$4.2M | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $0 | N/A | $0 | N/A | $0 |
| Net Income | -$3.0M+21.4% | -$3.8M | N/A | -$3.2M | N/A | -$4.0M | N/A | -$9.5M |
| EPS (Diluted) | $-0.47+26.6% | $-0.64 | N/A | $-0.86 | N/A | $-2.32 | N/A | $-0.45 |
APRE Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.3M-40.3% | $24.0M+5.9% | $22.7M-12.1% | $25.8M-14.6% | $30.2M-10.3% | $33.6M-40.8% | $56.8M-9.1% | $62.5M |
| Current Assets | $13.9M-40.9% | $23.6M+4.7% | $22.5M-12.2% | $25.6M-15.0% | $30.2M-9.9% | $33.5M-40.8% | $56.6M-9.0% | $62.2M |
| Cash & Equivalents | $13.7M-40.0% | $22.8M+5.8% | $21.6M-14.8% | $25.4M-11.9% | $28.8M-13.1% | $33.1M-37.6% | $53.1M-13.6% | $61.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.4M-27.0% | $4.7M-18.0% | $5.7M+4.0% | $5.5M+71.1% | $3.2M-19.9% | $4.0M-45.4% | $7.3M-19.3% | $9.1M |
| Current Liabilities | $2.7M-20.2% | $3.4M-23.4% | $4.4M+5.3% | $4.2M+30.1% | $3.2M-19.9% | $4.0M-45.4% | $7.3M-19.1% | $9.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $10.9M-43.5% | $19.3M+13.9% | $17.0M-16.4% | $20.3M-20.9% | $25.6M-3.7% | $26.6M-46.2% | $49.5M-7.3% | $53.4M |
| Retained Earnings | -$331.2M-3.2% | -$321.0M-4.2% | -$308.1M-1.1% | -$304.6M-3.7% | -$293.8M-0.8% | -$291.4M-60.8% | -$181.1M-4.5% | -$173.4M |
APRE Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M+9.7% | -$3.5M+6.1% | -$3.7M-66.8% | -$2.2M+44.2% | -$4.0M+39.0% | -$6.6M+35.2% | -$10.2M-23.6% | -$8.2M |
| Capital Expenditures | N/A | $0-100.0% | $7K | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | -$3.5M+6.3% | -$3.7M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0+100.0% | -$7K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $358K+166.3% | $134K | $0 | $0-100.0% | $99K | N/A | $1.7M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APRE Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -20.8%-6.7pp | -14.1% | N/A | -12.4% | N/A | -12.0% | N/A | -15.1% |
| Current Ratio | 5.20-1.8 | 7.01+1.9 | 5.14-1.0 | 6.15-3.3 | 9.42+1.0 | 8.37+0.6 | 7.73+0.9 | 6.88 |
| Debt-to-Equity | 0.31+0.1 | 0.24-0.1 | 0.34+0.1 | 0.27+0.1 | 0.12-0.0 | 0.150.0 | 0.15-0.0 | 0.17 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Aprea Therapeutics, Inc. profitable?
No, Aprea Therapeutics, Inc. (APRE) reported a net income of -$13.0M in fiscal year 2024.
What is Aprea Therapeutics, Inc.'s earnings per share (EPS)?
Aprea Therapeutics, Inc. (APRE) reported diluted earnings per share of $-2.45 for fiscal year 2024. This represents a 38.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aprea Therapeutics, Inc.'s EBITDA?
Aprea Therapeutics, Inc. (APRE) had EBITDA of -$14.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aprea Therapeutics, Inc.'s free cash flow?
Aprea Therapeutics, Inc. (APRE) generated -$13.6M in free cash flow during fiscal year 2024. This represents a -10.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aprea Therapeutics, Inc.'s operating cash flow?
Aprea Therapeutics, Inc. (APRE) generated -$13.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aprea Therapeutics, Inc.'s total assets?
Aprea Therapeutics, Inc. (APRE) had $24.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Aprea Therapeutics, Inc.'s capital expenditures?
Aprea Therapeutics, Inc. (APRE) invested $15K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Aprea Therapeutics, Inc. spend on research and development?
Aprea Therapeutics, Inc. (APRE) invested $9.4M in research and development during fiscal year 2024.
How many shares does Aprea Therapeutics, Inc. have outstanding?
Aprea Therapeutics, Inc. (APRE) had 5M shares outstanding as of fiscal year 2024.
What is Aprea Therapeutics, Inc.'s current ratio?
Aprea Therapeutics, Inc. (APRE) had a current ratio of 7.01 as of fiscal year 2024, which is generally considered healthy.
What is Aprea Therapeutics, Inc.'s debt-to-equity ratio?
Aprea Therapeutics, Inc. (APRE) had a debt-to-equity ratio of 0.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aprea Therapeutics, Inc.'s return on assets (ROA)?
Aprea Therapeutics, Inc. (APRE) had a return on assets of -54.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aprea Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Aprea Therapeutics, Inc. (APRE) had $22.8M in cash against an annual operating cash burn of $13.6M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Aprea Therapeutics, Inc.'s Piotroski F-Score?
Aprea Therapeutics, Inc. (APRE) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aprea Therapeutics, Inc.'s earnings high quality?
Aprea Therapeutics, Inc. (APRE) has an earnings quality ratio of 1.05x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.